Literature DB >> 24266364

Role of pathogens in multiple sclerosis.

Jane E Libbey1, Matthew F Cusick, Robert S Fujinami.   

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disease of the central nervous system (CNS). Although the etiology of MS is unknown, genetic and environmental factors play a role. Infectious pathogens are the likely environmental factors involved in the development of MS. Pathogens associated with the development or exacerbation of MS include bacteria, such as Mycoplasma pneumoniae and Chlamydia pneumoniae, the Staphylococcus aureus-produced enterotoxins that function as superantigens, viruses of the herpes virus (Epstein-Barr virus and human herpesvirus 6) and human endogenous retrovirus (HERV) families and the protozoa Acanthamoeba castellanii. Evidence, from studies with humans and animal models, supporting the association of these various pathogens with the development and/or exacerbation of MS will be discussed along with the potential mechanisms including molecular mimicry, epitope spreading and bystander activation. In contrast, infection with certain parasites such as helminthes (Schistosoma mansoni, Fasciola hepatica, Hymenolepis nana, Trichuris trichiura, Ascaris lumbricoides, Strongyloides stercolaris, Enterobius vermicularis) appears to protect against the development or exacerbation of MS. Evidence supporting the ability of parasitic infections to protect against disease will be discussed along with a brief summary of a recent Phase I clinical trial testing the ability of Trichuris suis ova treatment to improve the clinical course of MS. A complex interaction between the CNS (including the blood-brain barrier), multiple infections with various infectious agents (occurring in the periphery or within the CNS), and the immune response to those various infections may have to be deciphered before the etiology of MS can be fully understood.

Entities:  

Keywords:  bacteria; parasites; protozoa; superantigens; viruses

Mesh:

Year:  2013        PMID: 24266364      PMCID: PMC4369909          DOI: 10.3109/08830185.2013.823422

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  114 in total

1.  MULTIPLE SCLEROSIS AND POLIOMYELITIS.

Authors:  D C POSKANZER; K SCHAPIRA; H MILLER
Journal:  Lancet       Date:  1963-11-02       Impact factor: 79.321

Review 2.  Intravenous immunoglobulin in MS: promise or failure?

Authors:  Franz Fazekas; Siegrid Strasser-Fuchs; Otto R Hommes
Journal:  J Neurol Sci       Date:  2007-04-20       Impact factor: 3.181

3.  Intramolecular epitope spreading induced by staphylococcal enterotoxin superantigen reactivation of experimental allergic encephalomyelitis.

Authors:  Jeanne M Soos; Mustafa G Mujtaba; Joel Schiffenbauer; Barbara A Torres; Howard M Johnson
Journal:  J Neuroimmunol       Date:  2002-02       Impact factor: 3.478

4.  Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Ying C Q Zang; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Ann Neurol       Date:  2003-02       Impact factor: 10.422

5.  Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis.

Authors:  Frida Lundmark; Kristina Duvefelt; Ellen Iacobaeus; Ingrid Kockum; Erik Wallström; Mohsen Khademi; Annette Oturai; Lars P Ryder; Janna Saarela; Hanne F Harbo; Elisabeth G Celius; Hugh Salter; Tomas Olsson; Jan Hillert
Journal:  Nat Genet       Date:  2007-07-29       Impact factor: 38.330

6.  Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses.

Authors:  Kevin P Walsh; Miriam T Brady; Conor M Finlay; Louis Boon; Kingston H G Mills
Journal:  J Immunol       Date:  2009-07-08       Impact factor: 5.422

Review 7.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

8.  Multiple sclerosis: are protective immune mechanisms compromised by a complex infectious background?

Authors:  Bernd Krone; John M Grange
Journal:  Autoimmune Dis       Date:  2010-12-20

9.  B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity.

Authors:  Tomasz Brudek; Tove Christensen; Lars Aagaard; Thor Petersen; Hans J Hansen; Anné Møller-Larsen
Journal:  Retrovirology       Date:  2009-11-16       Impact factor: 4.602

10.  Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications.

Authors:  J O Virtanen; M Färkkilä; J Multanen; L Uotila; A J Jääskeläinen; A Vaheri; M Koskiniemi
Journal:  J Neurovirol       Date:  2007-08       Impact factor: 3.739

View more
  36 in total

1.  Neutralization of staphylococcal enterotoxin B by an aptamer antagonist.

Authors:  Kaiyu Wang; Longjie Gan; Li Jiang; Xianhui Zhang; Xiangyue Yang; Min Chen; Xiaopeng Lan
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

Review 2.  Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.

Authors:  Borros Arneth
Journal:  J Neurol       Date:  2018-02-08       Impact factor: 4.849

3.  Interactions of antisera to different Chlamydia and Chlamydophila species with the ribosomal protein RPS27a correlate with impaired protein synthesis in a human choroid plexus papilloma cell line.

Authors:  Abdullah Almamy; Christian Schwerk; Horst Schroten; Hiroshi Ishikawa; Abdul Rahman Asif; Bernhard Reuss
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

Review 4.  Inflammation in CNS neurodegenerative diseases.

Authors:  Jodie Stephenson; Erik Nutma; Paul van der Valk; Sandra Amor
Journal:  Immunology       Date:  2018-04-17       Impact factor: 7.397

Review 5.  Molecular functions of human endogenous retroviruses in health and disease.

Authors:  Maria Suntsova; Andrew Garazha; Alena Ivanova; Dmitry Kaminsky; Alex Zhavoronkov; Anton Buzdin
Journal:  Cell Mol Life Sci       Date:  2015-06-18       Impact factor: 9.261

Review 6.  Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities.

Authors:  Alexios-Fotios A Mentis; Efthimios Dardiotis; Nikolaos Grigoriadis; Efthimia Petinaki; Georgios M Hadjigeorgiou
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

7.  Chlamydia pneumoniae Infection and Inflammatory Diseases.

Authors:  Rebecca A Porritt; Timothy R Crother
Journal:  For Immunopathol Dis Therap       Date:  2016

8.  Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis.

Authors:  Steffen Haupeltshofer; Teresa Leichsenring; Sarah Berg; Xiomara Pedreiturria; Stephanie C Joachim; Iris Tischoff; Jan-Michel Otte; Tobias Bopp; Massimo C Fantini; Charlotte Esser; Dieter Willbold; Ralf Gold; Simon Faissner; Ingo Kleiter
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-03       Impact factor: 11.205

9.  FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.

Authors:  Caroline A Blanc; Hugh Rosen; Thomas E Lane
Journal:  J Neuroinflammation       Date:  2014-08-20       Impact factor: 8.322

Review 10.  Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.

Authors:  Júlia Leão Batista Simões; Julia Beatrice de Araújo; Margarete Dulce Bagatini
Journal:  Mol Neurobiol       Date:  2021-07-11       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.